We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Lumenis Plagued with Problems

By HospiMedica staff writers
Posted on 07 Jan 2003
As a result of a string of financial and other problems, Lumenis Ltd. (Yokneam, Israel) has announced that its CEO, Yacha Sutton, has retired. The board has formed a search committee to find a permanent CEO. In the meantime, the company's vice chairman has assumed CEO duties.

Lumenis, a leading global supplier of medical lasers, is being investigated by the US Securities and Exchange Commission (SEC), which is questioning the veracity of its financial statements, and has been sued by a former financial officer who charged he was terminated in retaliation for disclosing accounting irregularities. Nonetheless, the principal lender to Lumenis, Bank Hapoalim, has confirmed its continued support of the company.

Lumenis has become the world leader in the surgical CO2 market. The company was formed in April 2001 when ESC Medical Systems and Coherent Medical Group joined forces. Both were pioneers in the application of light to medical and esthetic procedures. Three years earlier, ESC had acquired Laser Industries, with its well-known Sharplan brand name. Recently, Lumenis introduced the UltraPulse SurgiTouch as the first "smart” laser. It is based on the CO2 laser technology of Coherent and the advanced scanning capability of the ESC Sharplan SurgiTouch.

Still, sales have not met the company's expectations. In announcing third quarter results in October 2002, CEO Sutton said, "Lower US esthetic sales and an adverse product mix impacted margins in the third quarter. Operating expenses, while reduced from previous levels due to our cost reduction program, were adversely affected by the costs associated with the gathering of documents and other information in connection with the SEC investigation.”


Related Links:
Lumenis

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
12-Channel ECG
CM1200B
New
Diagnostic Ultrasound System
MS1700C
New
Fetal and Maternal Monitor
F9 Series

Latest Business News

Boston Scientific Acquires Medical Device Company Intera Oncology

MEDICA 2024 to Highlight Hot Topics of MedTech Industry

Start-Ups To Once Again Play Starring Role at MEDICA 2024